Janssen gearing up for EULAR 2016
The European League Against Rheumatism Annual (EULAR) Congress is taking place in London, during 8–11 June. With over 4,000 abstracts submitted, nearly 200 sessions and poster tours on offer and over 14,000 rheumatologists and healthcare professionals attending, the Janssen Immunology team is getting ready to share their latest data with the rheumatology community, for both psoriatic arthritis and rheumatoid arthritis.
Did you know that psoriatic arthritis and rheumatoid arthritis affect more than 7.1 million people in Europe?. 1,2,3 That’s equivalent to the whole population of Serbia or Bulgaria!4
ARTHRITIS?
Rheumatoid arthritis is a chronic inflammatory disorder that occurs when the immune system attacks the lining of the membranes that surround joints.
If untreated, rheumatoid arthritis can cause painful swelling and destroys the cartilage and bone, and eventually result in permanent joint deformity. 1
ARTHRITIS?
Psoriatic arthritis is a chronic immune-mediated inflammatory disease characterised by both joint and surrounding tissue inflammation, as well as the skin lesions associated with psoriasis.
Symptoms of psoriatic arthritis include swelling, pain, stiffness of the joints and surrounding tissue, and reduced range of motion.2,3
A total of 12 abstracts presenting data from new clinical trials and real-world patient outcomes in rheumatoid arthritis and psoriatic arthritis respectively, will be presented during the congress.
Janssen is also pleased to be sponsoring two greatly anticipated symposia: ‘How much do we know about psoriatic arthritis?’ is taking place at 13:00–14:30 on Wednesday 8 June in the Capital Suite 14, ExCeL London, and will look into the current treatment options for PsA. The second, ‘Think rheumatoid arthritis – causes, consequences and management’, chaired by Professor Josef Smolen, will be taking place at 17:30–19:00 on Thursday 9 June in the Capital Suite 02, ExCeL London. The symposium will discuss intervention options and the psychological impact associated with rheumatic diseases.
The breadth of data and knowledge that is being shared at EULAR demonstrates Janssen’s continuing commitment to both researching and developing innovative interventions for these debilitating immune and inflammatory diseases.
1 National Rheumatoid Arthritis Society. European Fit for Work report. Available at http://www.nras.org.uk/european-fit-for-work-report (last accessed May 2016).
2 National Psoriasis Foundation. Factsheet: Psoriatic arthritis. Available at https://www.psoriasis.org/sites/default/files/psoriatic_arthritis_fact_sheet.pdf (last accessed May 2016).
3 Augustin M, et al. A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol venereol 2012;26(s4):1–16.
4 List of countries and dependencies by population. Available at https://en.wikipedia.org/wiki/List_of_countries_and_dependencies_by_population (last accessed May 2016).